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Summary
 
Cells of the innate immune system secrete cytokines early in immune responses that guide ma-
turing T helper (Th) cells along appropriate lineages. This study investigates the role of cyto-
kine networks, bridging the innate and acquired immune systems, in the pathogenesis of an or-
gan specific autoimmune disease. Experimental allergic encephalomyelitis (EAE), a demyelinating
disease of the central nervous system, is widely used as an animal model for multiple sclerosis.
We demonstrate that interleukin (IL)-12 is essential for the generation of the autoreactive Th1
cells that induce EAE, both in the presence and absence of interferon 
 
g
 
. The disease-promot-
ing effects of IL-12 are antagonized by IL-10 produced by an antigen nonspecific CD4
 
1
 
 T cell
which, in turn, is regulated by the endogenous production of IL-12. This unique immunoreg-
ulatory circuit appears to play a critical role in controlling Th cell differentiation and provides a
mechanism by which microbial triggers of the innate immune system can modulate autoim-
mune disease.
 
T
 
cells are classified into Th1/Th2 subsets based on the
array of cytokines they produce upon antigen stimula-
tion, which, in turn, dictates the nature of the immune re-
sponse (1). Studies in infectious disease and autoimmunity
models have demonstrated that immune responses to both
self- and foreign antigenic challenges are frequently domi-
nated by induction of a particular Th subset, with profound
consequences for clinical outcome (2, 3). Although the in-
flammatory effector function of Th1 cells is essential for the
clearance of intracellular pathogens, it is also responsible for
tissue damage typical of organ-specific autoimmunity (4–
13). Th2 cells, on the other hand, are critical for the clear-
ance of many helminthic infections and have been impli-
cated in the pathogenesis of systemic autoimmune diseases
driven by the production of autoreactive antibodies (14,
15). However, they are generally depicted as suppressor cells
or ineffectual bystanders in organ-specific autoimmune dis-
eases (16–20).
Experimental allergic encephalomyelitis (EAE)
 
1
 
 is a de-
myelinating disease of the central nervous system (CNS)
induced either by active immunization with myelin pro-
teins or by the adoptive transfer of myelin protein–reactive
T cells. The CD4
 
1
 
 T cell lines and clones that transfer EAE
invariably produce IFN-
 
g
 
 and/or TNF-
 
a
 
/lymphotoxin-
 
a
 
(LT
 
a
 
) on antigenic challenge in vitro (21–23). Lines and
clones with the same peptide/MHC specificities that have
been manipulated to produce Th2 rather than Th1 cyto-
kines generally lose their encephalitogenic potential and, in
certain circumstances, can act to suppress disease (24–28).
Furthermore, mRNA encoding Th1 cytokines is found in
the CNS during peak disease with levels falling at the time
of remission (29–31). Interventions to block the activity of
the Th1 cytokine, TNF-
 
a
 
, by use of neutralizing antibod-
ies (32, 33), soluble TNF I receptors (34, 35), or type 1
phosphodiesterase inhibitors (36, 37), lead to reversal of
EAE, whereas injection of recombinant TNF-
 
a
 
 triggers re-
lapses (38). Conversely, EAE has been treated successfully
by the administration of exogenous Th2 cytokines either
infused systemically or delivered locally by genetically engi-
neered myelin-reactive cells (39–42). Endogenous produc-
tion of IL-4 and IL-10, which counterregulate and antago-
nize Th1 cytokines, has been implicated in the initiation of
spontaneous remissions (29–31).
The prevailing dogma, shaped by such observations, de-
picts the inducers of EAE as polarized Th1 cells and caus-
ally links their Th1 phenotype with encephalitogenicity
(4). However, the regulation and function of individual cy-
tokines in EAE is more complex than the above studies im-
ply. Alteration in the systemic expression and/or activity of
cytokines believed to be important in the pathogenesis of
EAE has yielded paradoxical results with respect to clinical
outcome. For example, the injection of neutralizing anti-
bodies to IFN-
 
g
 
 exacerbated disease in five independent
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, exper-
imental allergic encephalomyelitis; iNOS, inducible nitric oxide synthase;
LT
 
a
 
, lymphotoxin-
 
a
 
; MBP, myelin basic protein.
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studies (43–47) and administration of recombinant IFN-
 
g
 
has repeatedly been found to have a protective effect (43,
47, 48). EAE has also been successfully induced in IFN-
 
g
 
knockout (
 
2
 
/
 
2
 
) and IFN-
 
g
 
–receptor knockout mice, and in
at least two cases the disease was more severe in the knock-
outs than in wild-type counterparts (49–51). Taken together,
these results suggest that IFN-
 
g
 
 can actually act to suppress
the development of EAE, either during the evolution of
encephalitogenic effectors or at a downstream event critical
to the formation of demyelinating plaques. The application
of the Th1/Th2 paradigm to EAE was most recently
brought into question by the successful induction of the
disease in double knockout mice deficient in expression of
the other two Th1 cytokines, TNF-
 
a
 
 and LT
 
a
 
 (52), and by
the failure to induce a more severe form of EAE in IL-4
 
2
 
/
 
2
 
mice in comparison to their wild-type counterparts (53).
To further complicate matters, a recent study demonstrated
that T cells that express a TCR transgene specific for mye-
lin basic protein (MBP) induce EAE in immunodeficient
recipients after culture under either Th1 or Th2 polarizing
conditions (54). This study, as well as one illustrating a sim-
ilar phenomenon in an animal model of diabetes (55), sug-
gests that T cells that do not fall into the classic Th1 subset
can nevertheless act as mediators of organ-specific autoim-
munity.
Thus far, most studies have been designed to investigate
the role of highly differentiated, polarized Th1/Th2 effec-
tor cells and their signature cytokines in EAE. An alterna-
tive strategy is to examine autoreactive cells during forma-
tive stages in their development in order to gain insight
into the factors that promote the evolution of naive autore-
active precursors into proinflammatory autoimmune effec-
tors. Among the factors currently known to influence pat-
terns of Th cell development, cytokines produced by cells
of the innate immune system are the most important. The
production of IL-12 by monocytes and dendritic cells re-
sults in Th1 differentiation, whereas the production of IL-10
by macrophages and a subset of B cells antagonizes the ac-
tivities of IL-12 (56–59). Hence, cells populating the innate
component of the immune system, stimulated by con-
served microbial products and structural elements, can se-
crete cytokines early in immune responses that can po-
tentially guide maturing Th cells along appropriate lineages
(60, 61). In autoimmune disease, this interplay between the
innate and adaptive responses may be subverted to promote
the development of autoreactive effectors. We have previ-
ously demonstrated that MBP-reactive cells can be con-
verted from a quiescent state into autoimmune effectors by
exposure to exogenous IL-12 or to microbial products that
induce IL-12 production by macrophages (62, 63). Other
studies have also demonstrated a disease-promoting effect
of IL-12 in EAE as well as other models of organ-specific
autoimmunity (7, 64, 65). Conversely, anti–IL-12 was
found to delay the onset of disease when administered short
term to recipients of primed Th1 EAE effectors, but severe
disease ensued immediately after withdrawal of therapy.
More prolonged administration of the neutralizing antise-
rum resulted in protective effects that persisted after cessa-
tion of treatment, but the treated animals were not fol-
lowed for a long enough period to determine whether they
would experience relapses. No effort was made in these
studies to analyze the role of IL-12 in the induction of the
Th1 effectors and the authors postulated that the protective
effects of anti–IL-12 at the late stage of disease pathogenesis
may have involved an interference with the ability of the
mature autoreactive cells to home to the CNS (64).
This study focuses on the contribution of cytokine pro-
duction by cells of the innate immune system to the gener-
ation and differentiation of Th1 autoreactive effector cells. Ini-
tially, we use cytokine-deficient mice to demonstrate that
IL-12 is absolutely essential for the pathogenesis of EAE,
both in the presence and absence of IFN-
 
g
 
. In a parallel
approach involving the neutralization of IL-12 in cytokine-
sufficient mice, we characterize a unique immunoregula-
tory circuit in which endogenous production of IL-12 sup-
presses IL-10 production by an antigen nonspecific CD4
 
1
 
 T
cell. This latter cell, which may represent a new member of
the innate immune system, appears to play a critical role in
regulating Th cell differentiation.
 
Materials and Methods
 
Mice.
 
SJL/J, C57BL/6, C57BL/10, BALB/c, BALB/c 
 
nu
 
/
 
nu
 
, and C.B-17 SCID mice were all obtained from the National
Cancer Institute (Frederick, MD). Breeding pairs of C57BL/6
IL-12
 
2
 
/
 
2
 
 (N6) and C57BL/6 IFN-
 
g2
 
/
 
2
 
 (N7) mice were
originally provided by J. Magram (Hoffman LaRoche, Nutley,
NJ) and Dyana Dalton and T. Stewart (Genentech Inc., South
San Francisco, CA), respectively. Breeding pairs of IL-4
 
2
 
/
 
2
 
 and
IL-10
 
2
 
/
 
2
 
 mice were originally obtained from R. Kuhn and W.
Muller (University of Koln, Koln, Germany) and backcrossed in
our facilities onto the C57BL/6 (N13) and C57BL/10 (N7)
backgrounds, respectively. All mice were housed under specific
pathogen-free conditions. They were exclusively female and be-
tween 8 and 12 wk of age when experiments were initiated.
 
Induction of EAE.
 
Bovine MBP was obtained from Sigma
Chemical Co. (St. Louis, MO). MBP
 
87–106
 
, corresponding to res-
idues 87–106 of murine MBP (VVHFFKNIVTPRTPPPQGK),
was synthesized by the Laboratory of Molecular Structure, Pep-
tide Synthesis Laboratory (NIAID, NIH, Bethesda, MD) and an-
alyzed and purified by high pressure liquid chromatography. For
induction of EAE by active immunization, mice were injected
with bovine MBP (400 
 
m
 
g) emulsified in CFA (1:1) by the sub-
cutaneous route over the left flank on day 0 and over the right
flank on day 7. Mice were examined daily and rated for severity
of neurological impairment as previously described (62, 63). For
disease induction by adoptive transfer, donor mice were immu-
nized with MBP
 
87–106
 
 (100 
 
m
 
g) or bovine MBP (400 
 
m
 
g) emulsi-
fied in CFA (1:1) by subcutaneous injection at four sites over the
flanks. 10–14 d later, draining LN cells (axillary and inguinal)
were removed and processed as previously described (62). Cells
were cultured for 96 h with MBP
 
87–106
 
 (50 
 
m
 
g/ml) or bovine
MBP (50 
 
m
 
g/ml) in RPMI 1640 containing 10% FCS and stan-
dard supplements (TCM). Recovered cells (5 
 
3
 
 10
 
7
 
) were in-
jected intraperitoneally into naive syngeneic recipients that were
examined daily for signs of EAE. In certain studies, the mice were
injected intraperitoneally with polyclonal goat anti–mouse IL-12
(0.5 
 
m
 
g per injection; a gift of Drs. D. Presky and M. Gately,
Hoffman-La Roche), normal goat IgG (0.5 mg per injection; 
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Sigma Chemical Co.), rat anti–mouse IL-10 (1 mg each of mAbs
SXC-1 and SXC-2 per injection; reference 66), or control rat IgG
(2 mg; Sigma Chemical Co.).
 
Cell Cultures.
 
Single-cell suspensions of spleen or LN tissue
were prepared by passage through wire mesh and red blood cells
lysed with ACK buffer (NIH Media Unit, Bethesda, MD). For
detection of cytokine production during primary culture, cells (4 
 
3
 
10
 
6
 
/ml) were cultured in TCM in 24-well plates (Costar Corp.,
Cambridge, MA) for 96–144 h. In some experiments, spleens
were depleted of various subpopulations before culture using
sheep antifluorescein biomag beads (Perspective Bioresearch Prod-
ucts, Cambridge, MA) together with FITC-conjugated mAbs spe-
cific for CD4, CD8, B220, and Mac-1 (PharMingen, San Diego,
CA). In other experiments, purified CD4
 
1
 
 T cells and B220
 
1
 
 B
cells were cocultured (2 
 
3
 
 10
 
5
 
 of each in 200 
 
m
 
l) in 96-well mi-
crotiter plates (Costar Corp.). The CD4
 
1
 
 T cells were isolated
using CD4 subset enrichment columns (R & D Systems, Inc.,
Minneapolis, MN) with 90–95% purity achieved. B cells were
positively selected to 93–98% purity by incubation with anti-
B220 microbeads followed by magnetic separation using VS
 
1
 
columns (Miltenyi Biotec, Inc., Auburn, CA).
For measurement of cytokine production by MBP-reactive
LN cells during secondary cultures, the cells were harvested and
washed extensively after 96 h of primary in vitro stimulation.
Then they were resuspended in fresh media (1 
 
3
 
 10
 
6
 
 cells/ml)
and supplemented with irradiated syngeneic splenocytes (3,000
rads; 4 
 
3
 
 10
 
6
 
 cells/ml) with or without MBP
 
87–106
 
 (50 
 
m
 
g/ml).
Supernatants were assayed 48 h later.
 
Cytokine ELISA.
 
IFN-
 
g
 
, IL-4, and IL-10 were quantified
using a sandwich ELISA technique based on noncompeting pairs
of antibodies as previously described (62). The lower limit of de-
tection for each assay was as follows: IFN-
 
g
 
, 12–24 pg/ml; IL-4,
8–16 pg/ml; and IL-10, 16–32 pg/ml.
 
Results
 
Induction of EAE in Cytokine-deficient Mice.
 
Previous stud-
ies have attempted to address the contribution of individual
cytokines to the pathogenesis of EAE by examining the
susceptibility of cytokine-deficient mice to disease induc-
tion. Unfortunately, a comparison of these studies was dif-
ficult as different myelin-derived antigens were used and
the genetically deficient mice were only backcrossed onto
“susceptible” backgrounds for two to four generations. To
avoid these problems, we used a single antigen to examine
the susceptibility of wild-type mice and several different
cytokine-deficient mice that had been backcrossed more
completely to either the C57BL/6 or the C57BL/10 back-
grounds. C57BL/6 wild-type mice were relatively resistant
to EAE, with only 31% of actively immunized individuals
exhibiting clinical symptoms (Fig. 1). Among the affected
cohort the mean peak clinical score was 2.67 
 
6
 
 0.8 and the
average day of onset was 8.2 
 
6
 
 0.4. On the other hand, IL-
12
 
2
 
/
 
2
 
 mice were completely resistant to disease whereas
IFN-
 
g2
 
/
 
2
 
 animals exhibited severe EAE at 100% inci-
dence (mean peak clinical score, 4.5 
 
6
 
 0.68; average day of
onset, 9.1 
 
6
 
 1.6). Surprisingly, the induction of EAE in the
IFN-
 
g2
 
/
 
2
 
 animals was completely prevented by the
administration of neutralizing antibody to IL-12, but not
isotype control antibody, during the course of active im-
munization (Fig. 1, 
 
top
 
). This result suggested that IL-12
promotes the development of EAE by an IFN-
 
g
 
–indepen-
dent mechanism. The failure of IL-12
 
2
 
/
 
2
 
 and anti–IL-
12–treated IFN-
 
g2
 
/
 
2
 
 mice to develop disease was not
secondary to the induction of a Th2 response as neither IL-4
nor IL-10 was detected after stimulation of LN cells from
these animals with MBP in vitro (data not shown). Inter-
estingly, the incidence and severity of disease in IL-4
 
2
 
/
 
2
 
mice was comparable to that of the C57BL/6 wild-type
controls (Fig. 1, 
 
bottom
 
; mean peak clinical score, 1.95 
 
6
 
0.7) with slightly delayed onset (13 d 
 
6
 
 3). By contrast IL-
10
 
2
 
/
 
2
 
 mice exhibited enhanced disease incidence and se-
verity in comparison to C57B/10 wild-type controls (Fig.
1, 
 
bottom
 
; mean peak clinical scores, 2.4 
 
6
 
 0.6 vs. 1 
 
6
 
 0.1
in IL-10
 
2
 
/
 
2
 
 and wild-type mice, respectively) with simi-
lar kinetics (average day of onset, 11.5 
 
6
 
 0.5 and 11 
 
6
 
 1.3,
respectively). LN cells from both the IL-4
 
2
 
/
 
2
 
 and IL-
10
 
2
 
/
 
2
 
 strains produced elevated levels of IFN-
 
g
 
 after
stimulation with MBP in vitro compared to LN cells from
wild-type mice (data not shown). A deficiency of MBP-
specific Th2 cells could, theoretically, be responsible for the
increased incidence of EAE, as well as the propensity for
Th1 cytokine production, in IL-10
 
2
 
/
 
2
 
 mice. However,
this explanation is unlikely since the IL-4
 
2
 
/
 
2 mice did not
differ significantly from controls with regard to those char-
acteristics and IL-4 is required for Th2 development (67).
Role of IL-12 in the Evolution of IFN-g–producing Encepha-
litogenic Effector T Cells. To define IL-12–dependent stage(s)
in the development of EAE effectors, we neutralized IL-12
during individual steps of an adoptive transfer protocol.
Susceptible female SJL mice were immunized once with
MBP87–106 peptide (the immunodominant epitope for H-2s
Figure 1. (A) Induction of
EAE in both wild-type and IFN-
g2/2 mice is dependent on the
presence of IL-12. C57BL/6
wild-type (n 5 66), IFN-g2/2
(n 5 89) and IL-122/2 (n 5
33) mice were immunized with
bovine MBP (400 mg) emulsified
in CFA (1:1) on days 0 and 7.
IFN-g2/2 mice were injected
intraperitoneally with 0.5 mg of
neutralizing anti–IL-12 antibody
(n 5 30) or control IgG (n 5 59)
on days 0, 3, 6, and 12. Mice
were examined for signs of neu-
rologic impairment from days 0
to 50. Mice with clinical scores
of 1 (indicating a limp tail) or
higher were considered symp-
tomatic. Data was pooled from
five independent experiments;
standard deviation reflects the
variability between individual
experiments. (B) IL-102/2 mice, but not IL-42/2 mice, exhibit
heightened susceptibility to EAE. C57BL/10 wild-type (n 5 32) and
C57BL/10 IL-102/2 (n 5 39) mice, and C57BL/6 wild-type (n 5 20)
and C57BL/6 IL-42/2 (n 5 15) mice, were immunized with MBP and
examined for clinical signs according to the protocol described above.
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strains) in CFA; 10 d later, draining LN cells were stimu-
lated with antigen in vitro for 4 d and then transferred into
naive syngeneic recipients. As both the in vivo immuniza-
tion and the in vitro boost are required for the generation
of encephalitogenic effectors, we treated mice with a poly-
clonal anti–IL-12 antiserum during the course of priming
and/or added the antiserum to the in vitro cultures. MBP-
reactive LN cells exposed to anti–IL-12 only during culture
were mildly inhibited in their ability to produce IFN-g on
subsequent antigenic challenge in vitro (Fig. 2 A), but were
unimpaired in their capacity to transfer disease (Fig. 2 B).
In contrast, LN cells from donor mice treated with anti–IL-
12 in vivo exclusively were severely compromised in their
ability to produce antigen-dependent IFN-g on secondary
challenge in vitro (Fig. 2 A) and their encephalitogenicity
was markedly decreased on adoptive transfer (Fig. 2 B). Ad-
ministration of anti–IL-12 both in vivo and in vitro abro-
gated IFN-g production in secondary cultures, but did not
further impair the ability of cells to transfer disease when
compared to cells from animals that were only exposed to
anti–IL-12 in vivo (Fig. 2, A and B).
The Protective Effect of Anti–IL-12 Is Partially Due to the In-
duction of IL-10. To investigate whether the MBP-reac-
tive cells from the susceptible SJL strain had assumed a Th2
phenotype after treatment with anti–IL-12 in vivo and/or
in vitro, we measured IL-4 in the supernatants of the pri-
mary and secondary cultures of the four experimental
groups studied in Fig. 2. We were unable to detect IL-4 in
any of the supernatants tested. On the other hand, both LN
cells and splenocytes from anti–IL-12 treated donors, but
not control IgG–treated donors, produced significant quan-
tities of IL-10 during the primary culture (Fig. 3 A). This
result raised the question of whether the suppression of the
encephalitogenic phenotype by anti–IL-12 treatment was
secondary, in part, to the production of IL-10 during the
activation of MBP-specific T cells. Indeed, neutralization
of IL-10 using a mixture of mAbs during both immuniza-
tion and the in vitro culture largely reversed the protection
from disease afforded by the treatment of donor mice with
anti–IL-12 (Fig. 3 B).
The Suppression of IL-10 Production by IL-12 Is Antigen and
IFN-g Independent. Initially, we postulated that the source
of IL-10 was an MBP-specific T cell population induced
during priming in the presence of anti–IL-12. However,
similar amounts of IL-10 were produced by cultures in the
presence or absence of MBP87–106 (data not shown). In fact,
IL-10 production was not at all dependent on immuniza-
tion with MBP in CFA as splenocytes from naive SJL mice
previously treated with anti–IL-12 produced as much IL-10
as splenocytes from identically treated animals immunized
with MBP (Fig. 4 A). An anti–IL-12 antiserum from a sep-
Figure 2. The ability of MBP-
reactive LN cells to produce
IFN-g and transfer disease is
compromised after neutralization
of IL-12 during antigen priming.
(A) SJL mice were immunized
with MBP87–106 (100 mg) in CFA
and injected intraperitoneally
with 0.5 mg of either control
IgG or goat anti–mouse IL-12
on days 0, 3, and 6. Draining LN
were harvested on day 10 and
LN cells were cultured in the
presence of MBP87–106 (50 mg/
ml) with anti–IL-12 (10 mg/ml)
or control IgG (10 mg/ml). 96 h
later the cells were washed ex-
tensively and restimulated for 48 h
with antigen and irradiated syn-
geneic splenocytes to measure
IFN-g production. The values
indicated represent the means
and standard deviations of five
independent experiments using
a total of 25–30 donor mice/
group. (B) Cells (5 3 107) from
the four groups described in A
(exposed to control IgG only
[filled squares]; anti–IL-12 in vitro
[open circles]; anti–IL-12 in vivo
[filled circles]; and anti–IL-12 both in vivo and in vitro [open squares]) were
injected intraperitoneally into naive syngeneic recipients and recipient
animals were evaluated for neurological impairment. The incidence of
disease was 90.5, 80, 51, and 29%, respectively. Results were pooled from
five independent experiments with a total of 25–35 recipient mice in
each group.
Figure 3. Systemic adminis-
tration of anti–IL-12 elicits IL-10
production by lymphoid tissue
from MBP-primed mice. The
protection from EAE mediated
by anti–IL-12 is largely reversed
by neutralization of IL-10. (A)
Spleens and draining LN were
removed from SJL mice that had
been immunized with MBP87–106
10 d earlier and treated with ei-
ther anti–IL-12 or control IgG
according to the protocol de-
scribed in Fig. 2. Splenocytes and
LN cells were stimulated with
antigen and supernatants were
assayed for IL-10 production at
96 h. Results represent the
means and standard deviations of
six independent experiments in
which cells were pooled from 4–5
mice per group per experiment.
(B) Draining LN were removed
from MBP87–106 primed SJL mice
that had been injected with con-
trol IgG (filled squares), anti–IL-
12 (filled circles) or a combination
of anti–IL-12 and anti–IL-10
(open triangles) according to the
schedule described in Fig. 2. LN
cells from each group were stimulated with MBP87–106 for 96 h, in the
presence (open triangles) or absence (filled symbols) of anti–IL-10, washed
extensively, and then injected (5 3 107) into naive syngeneic recipients.
The incidence of disease was 87, 58, and 95% among recipients of control
IgG–, anti–IL-12–, and anti–IL-12/anti–IL-10–treated splenocytes, re-
spectively. The results shown in the figure are mean clinical scores ob-
tained from three independent experiments with a total of 20–30 recipi-
ent mice per experimental group.541 Segal et al.
arate source (sheep anti–mouse IL-12; gift of Genetics In-
stitute, Cambridge, MA) was equally effective (not shown).
Since mRNA encoding IL-12 p40 and p35 has been
found in the spleen and lymph node of naive mice (68),
these results are consistent with the possibility that a low
baseline level of IL-12 tonically suppresses an IL-10 pro-
ducing cell in lymph node and spleen. IL-12 could act di-
rectly on a cell bearing IL-12 receptor b1 and b2 chains
or indirectly through the induction of IFN-g. To clarify
the role of IFN-g in IL-12–mediated suppression of IL-10,
C57BL/6 IFN-g2/2 and wild-type mice were treated with
anti–IL-12 or control IgG. Splenocytes from IFN-g2/2
mice treated with anti–IL-12, but not control IgG, pro-
duced large quantities of IL-10, at levels comparable to that
produced by wild-type splenocytes from identically treated
donors (Fig. 4 B). Thus, IL-12 suppresses IL-10 production
by an IFN-g–independent mechanism.
IL-10 Is Produced by Anti–IL-12–treated CD41 T Cells,
but They Require the Presence of B Cells as Accessory Cells In
Vitro. To define which cell type was responsible for IL-
10 production after treatment with anti–IL-12 in vivo, we
compared IL-10 production by splenocytes from anti–IL-
12–treated nu/nu, C.B-17 SCID, and wild-type BALB/c
mice. Splenocytes from nu/nu and SCID mice failed to
produce detectable IL-10, whereas spleen cells from normal
BALB/c mice produced amounts of IL-10 comparable to
those produced by spleen cells from similarly treated SJL
mice (Fig. 5 A). As these results clearly implicate the T cell
as the source of IL-10 production after anti–IL-12 treat-
ment, we depleted various subpopulations from anti–IL-
12–treated SJL spleen preparations before culture and mea-
sured IL-10 levels in supernatants 96 h later. As expected,
Figure 4. Suppression of IL-10
production by endogenous IL-12
is antigen and IFN-g indepen-
dent. (A) Spleens were harvested
from naive or MBP87–106-primed
SJL mice that had been injected
with anti–IL-12 or control IgG
on days 210, 26, and 23 before
killing. Supernatants were as-
sayed for IL-10 after 96 h of cul-
ture. Results represent the means
of four independent experi-
ments with groups consisting of
5–7 mice in each experiment.
Standard deviations reflect the
variability between individual
experiments. (B) Naive C57BL/
6 wild-type and IFN-g2/2
mice were treated as in A. Re-
sults represent the means and
standard deviations of two inde-
pendent experiments in which
spleens were pooled from four
mice in each group.
Figure 5. After neutralization of IL-12, IL-10 is produced by antigen
nonspecific CD41 T cells in collaboration with B cells. Spleens were har-
vested from unimmunized mice that had been injected intraperitoneally
with 0.5 mg of control IgG or anti–IL-12 on days 210, 26, and 23 be-
fore killing. Supernatants were collected for assay of IL-10 after 96–120 h
of culture. (A) IL-10 production by splenocytes from BALB/c wild-type
(w/t), nu/nu, and SCID mice at 96 h. Results represent means and stan-
dard deviations of two independent experiments in which spleens were
pooled from 3–5 mice in each group in each experiment. (B) Splenocytes
from anti–IL-12 treated SJL mice (n 5 5–6) were depleted of various sub-
populations using sheep antifluorescein biomag beads and FITC-conju-
gated mAbs specific for the cell surface markers indicated. Recovered cells
(4 3 106 cells/ml) from each group were cultured and supernatants as-
sayed for IL-10 after 120 h. In each case, the recovered cells were 99–
100% free of the depleted population as determined by flow cytometry
using PE-conjugated mAbs (not shown). Results represent means and
standard deviations of three independent experiments. Whole spleen and
subpopulation preparations derived from control IgG–treated donors
failed to produce detectable IL-10 (not shown). (C) CD41 T cells and
B2201 B cells purified from spleens of anti–IL-12 or control IgG–treated
SJL mice (n 5 4–7/group) were cocultured (2 3 105 of each in 200 ml) in
96-well microtiter plates. Supernatants were collected at 120 h to quantify
IL-10 levels. Results represent means and standard deviations of four in-
dependent experiments. Levels of purity ranged from 90 to 95% for CD41
T cells and 93-98% for B2201 B cells as assessed by flow cytometry (not
shown). (D) CD41 T cells from spleens of anti–IL-12–treated C57BL/10
wild-type or IL-102/2 mice were cocultured with B2201 B cells puri-
fied from spleens of either anti–IL-12 or control IgG–treated donors (2 3
105 of each in 200 ml). An asterisk (*) denotes B cells taken from anti–IL-
12–treated mice. Supernatants were collected at 144 h to quantify IL-10
levels. Results represent means and standard deviations of two indepen-
dent experiments. Levels of purity ranged from 92 to 94% for CD41 T
cells and from 95 to 99% for B2201 B cells. Three to five donor mice
were used for each group in each experiment. CD41 T cells purified from
control IgG–treated donors failed to produce IL-10 irrespective of the B
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depletion of CD41 cells abrogated IL-10 production,
whereas depletion of CD81 and Mac11 cells had no effect.
Surprisingly, the B2201-depleted splenocytes produced
significantly less IL-10 than the whole splenocyte popula-
tion (Fig. 5 B). Furthermore, neither CD41 T cells nor
B2201 cells purified from spleens of anti–IL-12–treated do-
nors produced IL-10 when cultured separately, whereas IL-10
production was restored when the two subpopulations were
recombined (Fig. 5 C). CD41 T cells from anti–IL-12–treated
donors produced similar levels of IL-10 whether combined
with purified B cells from control IgG or anti–IL-12–treated
wild-type donors (Fig. 5 C), or with B cells from control
IgG–treated IL-102/2 mice (Fig. 5 D). Conversely,
CD41 cells from control IgG-treated wild-type donors or
anti–IL-12–treated IL-102/2 donors failed to produce
detectable IL-10 when combined with B cells from any of
the sources mentioned (Fig. 5, C and D).
Splenocytes from Anti–IL-12–treated Naive Mice Inhibit the
Induction of EAE. The abrogation of the protective effects
of anti–IL-12 by coinjection of anti–IL-10 (Fig. 3 B) and
the increased incidence of EAE in IL-102/2 mice (Fig. 1)
strongly suggested that IL-10 plays a downregulatory role
in the generation of EAE effector cells. To directly demon-
strate that the IL-10–producing CD41 T cell, generated in
the absence of antigenic priming, can downregulate the
generation of EAE effectors, we performed an adoptive
transfer study. SJL mice were injected with splenocytes from
anti–IL-12– or control IgG–treated syngeneic donors and
then immunized with bovine MBP according to the sched-
ule shown in Fig. 1. Splenocytes from anti–IL-12–treated,
but not control IgG–treated, SJL mice significantly inhib-
ited the induction of EAE (Fig. 6) thereby directly demon-
strating the biologic importance of the IL-10–producing
CD41 T cells whose presence is revealed when animals are
treated with anti–IL-12.
Discussion
These studies demonstrate a number of novel mecha-
nisms by which cytokine production by the innate immune
system controls an autoimmune response mediated by cells
within the adaptive immune system. In the model systems
we have used, IL-12 produced by macrophages and/or
dendritic cells plays a critical role in the generation of au-
toimmune effectors, while IL-10 production by antigen
nonspecific regulatory CD41 T cells subserves a counter-
regulatory or suppressive function. During the induction of
EAE in susceptible strains of mice, the homeostatic balance
maintained between these antagonistic cytokines is upset to
favor IL-12, the production of which is stimulated by my-
cobacterial components contained in the adjuvant. On the
other hand, the enhanced susceptibility to EAE of IL-102/2
mice may be secondary to the loss of the dominant sup-
pressive functions of this cytokine.
Although one might have predicted that IFN-g would
be indispensable for the generation and function of autoim-
mune effector cells, studies using anti–IFN-g mAbs and
IFN-g2/2 and IFN-g–receptor2/2 strains have uniformly
demonstrated that IFN-g is not required and in many cases
exerts a protective effect in EAE (43, 45, 49, 51). It was
therefore somewhat surprising that IL-122/2 mice were
resistant to EAE and that treatment of IFN-g2/2 mice
with anti–IL-12 prevented EAE. Furthermore, the genera-
tion of EAE effectors could be markedly inhibited by treat-
ment of highly susceptible SJL mice with anti–IL-12 during
the course of priming alone. Taken together, these results
demonstrate for the first time that a cytokine implicated
in the pathogenesis of EAE, namely IL-12, is indispensable
for its manifestation, whereas the effector molecules IFN-g,
TNF-a, and LTa appear to be redundant (50, 52). These
results should be contrasted with the requirements for both
IL-12 and IFN-g in mediating resistance to a number of
intracellular pathogens including Toxoplasma gondii, Myco-
bacterium tuberculosis, and Listeria monocytogenes (69-71). Al-
though IFN-g–independent actions have been attributed
to IL-12 in the past (72, 73, 57), in only one other case has
such an action been reported to affect the pathogenesis of
disease. Taylor and Murray (74) found that treatment of
IFN-g2/2 mice infected with Leishmania donovani with
exogenous IL-12 induced leishmanicidal activity and also
partially restored the near-absent tissue granulomatous re-
sponse. The action of IL-12 against L. donovani was TNF-
a–dependent and involved upregulation of inducible nitric
oxide synthase (iNOS). It was unclear from this study
whether the protective effects of IL-12 were mediated by
antigen-specific CD41 T cells or by NK cells. Neverthe-
less, induction of the TNF-a/iNOS pathway may also be
partially responsible for the IFN-g–independent actions of
IL-12 in EAE. We have detected high levels of mRNA en-
coding both TNF-a and iNOS in the spinal cords of ac-
tively immunized C57BL/6 IFN-g2/2 mice and markedly
reduced levels after treatment with anti–IL-12 (unpublished
Figure 6. Splenocytes from
anti–IL-12-treated naive mice
directly suppress the induction of
EAE. SJL mice were injected
with splenocytes (1 3 108)
pooled from 5–7 anti–IL-12–
treated or control IgG–treated
syngeneic donors, or they were
left untreated. Mice from all
three groups were subsequently
immunized with bovine MBP in
CFA 1 and 7 d later. (A) Results
represent the percent of mice
that remained healthy (clinical
score of 0) over the 30 d period
between the second immuniza-
tion and killing. The experiment
shown consisted of 10 recipients
of anti–IL-12–treated spleno-
cytes, 14 recipients of control
IgG–treated splenocytes, and 26
mice that were not pretreated.
(B) The mice described in A
were rated daily for signs of neu-
rologic impairment according to
the scale used in Fig. 2.543 Segal et al.
data). Although treatment of mice with anti–TNF-a has
been shown to prevent EAE, the contribution of TNF-a
to the pathogenesis of demyelination has been difficult to
define because the therapeutic effects of anti–TNF-a ap-
peared to have been mediated by prevention of entry of
pathogenic T cells into the CNS (32). It would therefore
be of interest to assess whether treatment with anti–TNF-a
and/or anti–LTa are able to protect IFN-g2/2 mice
from disease at a time point when pathogenic effector cells
have already entered the CNS. It would also be of interest
to determine whether administration of recombinant
TNF-a reverses the protection afforded by the anti–IL-12
treatment of actively immunized IFN-g2/2 mice.
Because it has previously been reported that IL-122/2
mice mount a Th2 response when infected with L. major,
whereas wild-type mice mount a Th1 response (75), we
intensively investigated whether anti–IL-12–treated SJL
mice develop a Th2 response when immunized with MBP
in CFA. Although no evidence for antigen-specific IL-4
production was observed, we consistently observed anti-
gen-independent IL-10 production. The IL-10–producing
population implicated has several unique properties that
distinguish it from conventional Th2 memory cells. After
anti–IL-12 treatment, it was as readily obtained from naive
mice as from mice that had been previously immunized.
The tonic inhibition of IL-10 production by the constitu-
tive presence of IL-12 in vivo is an IFN-g–independent ac-
tivity as upregulation of IL-10 production was also seen
when IFN-g2/2 mice were treated with anti–IL-12. Cell
purification studies demonstrated that the IL-10 producing
cell was a CD41 T cell, but required coculture with B cells
for induction of IL-10 production in vitro; we have not yet
evaluated other antigen-presenting cell types for their po-
tential to activate IL-10 production by these CD41 T cells.
The CD41 IL-10–producing cell resembles the IL-4 pro-
ducing CD41, NK1.11 cell in that it produces cytokines in
the absence of priming and therefore appears to be a mem-
ber of the newly recognized category of unconventional
“natural” T cells in the innate immune system that guide
adaptive responses through the production of Th1/2-mod-
ulating cytokines (76, 77). The induction of IL-4 produc-
tion by CD41NK1.11 T cells in response to CD1d stimu-
lation (78, 61) raises the possibility that a nonclassical MHC
molecule may also serve as the ligand for the IL-10 pro-
ducer and that the IL-10 producing T cell is responding
to an autoantigen presented by the B cell. Currently we
are conducting experiments to clarify the nature of the in-
teraction between the B and T cells responsible for IL-10
production. It should be noted that we did not observe en-
hanced IL-10 production by spleen cells from IL-122/2
mice, but this may be secondary to adaptive processes that
have taken place in the animal in the absence of IL-12.
The production of IL-10 by the CD41 T cells is highly
significant biologically as coinjection of anti–IL-10 largely
reversed the autoimmune suppressive effects of anti–IL-12.
Most importantly, IL-10 producing cells from anti–IL-12–
treated naive mice markedly suppressed the induction of
EAE after transfer into sensitized recipients. It is also likely
that the increased incidence of EAE that we observed in
IL-102/2 mice is due to the functional absence of this
immunoregulatory cell. The concept that exposure of de-
veloping autoimmune effector cells to IL-10 hinders their
development is supported by an earlier study in which EAE
was suppressed by the administration of recombinant IL-10
to rats during priming (40). It remains to be seen if this
CD41 IL-10–producing T cell plays a broader role in im-
mune surveillance by preventing organ-specific autoimmu-
nity. The high incidence of spontaneous autoimmune phe-
nomena in IL-102/2 mice suggest that this might be the
case (79). The innate immune system appears to be biased
towards the development of inflammatory immune re-
sponses as IL-10 production is constitutively suppressed by
IL-12. Therefore, CD41 IL-10–producing T cells may
be needed to curtail overzealous responses to acute infec-
tions that would otherwise lead to immunopathology. The
slightly delayed expression of IL-10, as compared to IL-12
and other proinflammatory cytokines, in several infectious
disease models make it a particularly effective downregulator
of the IL-12 response (58). The importance of this negative
regulatory role of IL-10 is highlighted by the emergence of
a lethal immune response, characterized by overproduction
of IL-12, IFN-g, and TNF-a, in IL-102/2 mice infected
with T. gondii (80).
Thus far efforts to manipulate cytokine production to al-
ter the course of autoimmune disease have been focused on
modification of the adaptive immune response. Although
positive results have been reported, these interventions were
mainly effective when administered early in the evolution
of the disease before the expression of clinical signs (39, 42,
64). Furthermore, recent reports of Th2-mediated autoim-
munity suggest that approaches to induce immune devia-
tion of Th1 effector cells may also ultimately result in im-
munopathology (54, 55). Collectively, our studies strongly
suggest that manipulation of the cytokine milieu, the IL-12/
IL-10 balance, maintained by cells of the innate immune
system, can have profound effects on the incidence of au-
toimmune disease. In chronic autoimmune diseases that
progress as a result of the continuous reactivation of au-
toantigen-specific memory T cells, it would be unlikely
that attempts to block IL-12 production or enhance IL-10
production would be therapeutically useful. On the other
hand, relapsing remitting autoimmune disease may provide
a unique opportunity for effective intervention employed
during periods when new effectors, capable of initiating re-
lapses, are recruited from a naive precursor pool. Studies
documenting the phenomenon of determinant spreading in
EAE and multiple sclerosis suggest that relapses are attribut-
able in large part to the activation of naive T cells specific
for cryptic epitopes during or after the peak of the initial
episode (81–83). We have previously suggested that IL-12
production in response to an infectious insult during disease
remission may lead to recruitment of Th1 cells (63); con-
sideration should be given to the prophylactic use of IL-12
antagonists and/or IL-10 in patients with autoimmune dis-
eases during epidemic outbreaks that have been associated
with autoimmune sequelae.544 Control of Autoimmunity by an IL-10/IL-12 Immunoregulatory Circuit
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